Japan Heart Failure Drugs Market

ID: MRFR/MED/50690-HCR
200 Pages
Vikita Thakur
Last Updated: February 06, 2026
Japan Heart Failure Drugs Market Research Report: Size, Share, Trend Analysis By Drug Class (Angiotensin-Converting Enzyme Inhibitors, Beta Blockers, Diuretics, Angiotensin II Receptor Blockers, Mineralocorticoid Receptor Antagonists), By Administration Route (Oral, Intravenous, Subcutaneous), By Patient Type (Acute Heart Failure, Chronic Heart Failure, Heart Failure with Preserved Ejection Fraction) and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Growth Outlook & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Japan Heart Failure Drugs Market

Market Size

Forecast Period2025 - 2035
CAGR (2025 - 2035)3.21%
2024 Market Size$ 1,830 Million
2025 Market Size$ 1,888.74 Million
2035 Market Size$ 2,590 Million

Key Players

Novartis
Bristol-Myers Squibb
Merck & Co
Amgen
Bayer
Pfizer
Trends
  • Aging Population Impact
  • Regulatory Advancements
  • Personalized Medicine Trends
Opportunities
  • Growing Awareness and Education
  • Advancements in Drug Development
  • Increased Healthcare Expenditure
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Medical Device, BY Drug Class (USD Million)
      1. 4.1.1 Angiotensin-Converting Enzyme Inhibitors
      2. 4.1.2 Beta Blockers
      3. 4.1.3 Diuretics
      4. 4.1.4 Angiotensin II Receptor Blockers
      5. 4.1.5 Mineralocorticoid Receptor Antagonists
    2. 4.2 Medical Device, BY Administration Route (USD Million)
      1. 4.2.1 Oral
      2. 4.2.2 Intravenous
      3. 4.2.3 Subcutaneous
    3. 4.3 Medical Device, BY Patient Type (USD Million)
      1. 4.3.1 Acute Heart Failure
      2. 4.3.2 Chronic Heart Failure
      3. 4.3.3 Heart Failure with Preserved Ejection Fraction
    4. 4.4 Medical Device, BY Distribution Channel (USD Million)
      1. 4.4.1 Hospital Pharmacy
      2. 4.4.2 Retail Pharmacy
      3. 4.4.3 Online Pharmacy
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Medical Device
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Medical Device
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Novartis (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bristol-Myers Squibb (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Merck & Co (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Amgen (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Bayer (DE)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Pfizer (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 GSK (GB)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 AstraZeneca (GB)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Roche (CH)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 JAPAN MARKET ANALYSIS BY DRUG CLASS
    3. 6.3 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE
    4. 6.4 JAPAN MARKET ANALYSIS BY PATIENT TYPE
    5. 6.5 JAPAN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    6. 6.6 KEY BUYING CRITERIA OF MEDICAL DEVICE
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF MEDICAL DEVICE
    9. 6.9 DRIVERS IMPACT ANALYSIS: MEDICAL DEVICE
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: MEDICAL DEVICE
    11. 6.11 SUPPLY / VALUE CHAIN: MEDICAL DEVICE
    12. 6.12 MEDICAL DEVICE, BY DRUG CLASS, 2024 (% SHARE)
    13. 6.13 MEDICAL DEVICE, BY DRUG CLASS, 2024 TO 2035 (USD Million)
    14. 6.14 MEDICAL DEVICE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
    15. 6.15 MEDICAL DEVICE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Million)
    16. 6.16 MEDICAL DEVICE, BY PATIENT TYPE, 2024 (% SHARE)
    17. 6.17 MEDICAL DEVICE, BY PATIENT TYPE, 2024 TO 2035 (USD Million)
    18. 6.18 MEDICAL DEVICE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    19. 6.19 MEDICAL DEVICE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Million)
      2. 7.2.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.2.3 BY PATIENT TYPE, 2025-2035 (USD Million)
      4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

Japan Japan Heart Failure Drugs Market Segmentation

Japan Heart Failure Drugs Market By Drug Class (USD Million, 2025-2035)

  • Angiotensin-Converting Enzyme Inhibitors
  • Beta Blockers
  • Diuretics
  • Angiotensin II Receptor Blockers
  • Mineralocorticoid Receptor Antagonists

Japan Heart Failure Drugs Market By Administration Route (USD Million, 2025-2035)

  • Oral
  • Intravenous
  • Subcutaneous

Japan Heart Failure Drugs Market By Patient Type (USD Million, 2025-2035)

  • Acute Heart Failure
  • Chronic Heart Failure
  • Heart Failure with Preserved Ejection Fraction

Japan Heart Failure Drugs Market By Distribution Channel (USD Million, 2025-2035)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035